Evidence map›Paper›PMID 39596795›Full record

ArticleAntibiotics (Basel, Switzerland)2024

Tigecycline Containing Polymethylmethacrylate Cement Against MRSA, VRE, and ESBL-In Vitro Mechanical and Microbiological Investigations.

Michael Abramowicz, Andrej Trampuz, Klaus-Dieter Kühn

Abstract read
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Michael AbramowiczKABEG, LKH Villach, 9500 Villach, Austria.
Andrej TrampuzFaculty of Health, School of Clinical Medicine, Queensland University of Technology (QUT), Brisbane 4006, Australia.
Klaus-Dieter KühnDepartment of Orthopaedics and Trauma, Medical University Graz, 8036 Graz, Austria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe use of antibiotic-loaded bone cements (ALBCs) in arthroplasty has been well established for the prevention and treatment of infections. Tigecycline (Tig), a broad-spectrum antibiotic, has shown efficacy against various pathogens, including vancomycin-resistant strains.

methodISO and DIN mechanical and microbiological inhibition zone tests were performed on PMMA cement with manually added Tigecycline.

resultsManually adding 0.5 and 1.0 g Tigecycline to PMMA always meets the mechanical requirements of ISO and DIN standards. Mixtures containing 0.5 g were microbiologically effective for up to 7 days and those containing 1.0 g were effective for 28-42 days.

conclusionIn revision surgery, manually adding Tigecycline in doses of 0.5-1 g to 40 g of PMMA is effective against MRSA, VRE, and ESBL without negatively affecting the cement's properties.

Indexed as

efficacyESBLmechanical propertiesMRSAPMMAtigecyclineVRE

Identifiers

PMID39596795
PMCPMC11591008

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.